A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Abstract Background Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharma...

Full description

Bibliographic Details
Main Authors: Kathleen Weisel, Scott Berger, Katie Thorn, Peter C. Taylor, Charles Peterfy, Hilary Siddall, Debra Tompson, Susanne Wang, Emilia Quattrocchi, Susan W. Burriss, Jochen Walter, Paul Peter Tak
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Arthritis Research & Therapy
Subjects:
Pharmacokinetics
Pharmacodynamics
Receptor-interacting protein kinase 1
RIPK1
Rheumatoid arthritis
Online Access:https://doi.org/10.1186/s13075-021-02468-0

Internet

https://doi.org/10.1186/s13075-021-02468-0

Similar Items